Renal Denervation in Chronic Heart Failure (REACH)
Status and phase
Conditions
Treatments
Details and patient eligibility
About
Renal denervation can be carried out for heart failure
Full description
There are theoretical reasons why renal denervation might be beneficial for patients with chronic heart failure. It is not known whether they would suffer large drops in blood pressure which might compromise safety.
This pilot study required patients to remain in hospital for one week during which they had careful monitoring of blood pressure with the ability to halt the trial if any patient suffered any dangerous effect such as a large drop in blood pressure. It also monitored blood pressure after discharge for six months.
Enrollment
Sex
Volunteers
Inclusion criteria
-Patients were required to have chronic symptomatic systolic heart failure (NYHA class III or IV) on maximal tolerated medical therapy, including beta-blocker, ACE inhibitor or angiotensin receptor blocker, and spironolactone.
Exclusion criteria
- Clinically unstable patients or those with significant valvular disease
- An estimated glomerular filtration rate <35 ml/min
- Unfavourable renal anatomy
- Tortuous femoral arteries were not eligible
Trial design
Primary purpose
Allocation
Interventional model
Masking
7 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal